Introduction: Ceritinib, 750 mg fasted, is approved for treatment of patients with ALK receptor tyrosine kinase gene (ALK)-rearranged (ALK-positive) NSCLC previously
with ALK-positive NSCLC while maintaining similar exposure.
Methods: ASCEND-8 is a multicenter, randomized, openlabel, phase 1 study. Part 1 investigated the steady-state pharmacokinetics (PK) and safety of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg fasted in patients with advanced ALK-positive NSCLC who were either treatment naive or pretreated with chemotherapy and/or crizotinib. Part 2 will assess efficacy and safety of ceritinib in treatment-naive patients.
Results: As of June 16, 2016 
Introduction
ALK receptor tyrosine kinase gene (ALK) rearrangements serve as a key oncogenic driver and occur in 3% to 7% of patients with NSCLC. 1, 2 Ceritinib, a nextgeneration selective oral anaplastic lymphoma kinase (ALK) inhibitor, is approved at a dose of 750 mg/d under fasted conditions for the treatment of patients with metastatic ALK-positive NSCLC. 3 In phase 1 and 2 studies, ceritinib, 750 mg/d fasted, demonstrated clinically meaningful and durable responses in ALK inhibitor-pretreated and ALK inhibitor-naive patients with advanced ALK-positive NSCLC. [4] [5] [6] Further, in randomized, global phase 3 trials, ceritinib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy in patients with advanced ALK-positive NSCLC who were treatment naive (ASCEND-4 study) 7 or previously treated with crizotinib and one or two prior chemotherapy regimens (ASCEND-5 study). 8 Data from phase 1 to phase 3 studies in patients with advanced ALK-positive NSCLC have shown that the gastrointestinal (GI) toxicities diarrhea, nausea, and vomiting are the most frequent adverse events (AEs) after ceritinib treatment [4] [5] [6] [7] [8] ; these toxicities generally occur early in treatment. 4 In the ASCEND-4 study, the most frequently reported AEs (all grades, all causality) in the ceritinib arm (n ¼ 189) were diarrhea (85%), nausea (69%), and vomiting (66%), predominantly of grade 1/2. The proportion of patients with grade 3 or 4 AEs of diarrhea, nausea, and vomiting in the ceritinib arm were low at 5%, 3%, and 5%, respectively. 7 In the ASCEND-5 study, the most frequently reported AEs (all grades, all causality) in the ceritinib arm (n ¼ 115) were diarrhea (72%), nausea (66%), and vomiting (52%). The proportions of patients with grade 3 or 4 AEs of diarrhea, nausea, and vomiting in the ceritinib arm were similar (4%, 8%, and 8%, respectively). 8 These GI toxicities were managed with concomitant medication, study drug interruption, or dose reduction. 7, 8 Dosing with food has been shown to improve the GI tolerability of orally administered tyrosine kinase inhibitors. 9, 10 In a food-effect trial, a high-fat meal increased bosutinib exposure twofold but led to better GI tolerability when coadministered with food. 10 As a result, bosutinib was coadministered with a meal in the pivotal trial and subsequent trials, and it was advised that bosutinib be taken once daily with food in the label.
Similarly, ceritinib demonstrates a positive food effect. In a food-effect study of ceritinib (A2101) in healthy subjects, compared with the fasted state, a low-fat meal (w330 cal and 9 g of fat) increased the maximum concentration of drug in plasma (C max ) and area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC inf ) of a single oral 500-mg dose of ceritinib by 43% and 58%, respectively, whereas a highfat meal (w1000 cal and 58 g of fat) increased C max and AUC inf by 41% and 73%, respectively. Although the enhancement of ceritinib absorption was shown to be more pronounced with a high-fat meal (58 g of fat) than with a low-fat meal or a light snack, the difference is not considered substantial. In another study of ceritinib (A2108) in healthy subjects, compared with the fasted state, a light snack (w100-300 cal and 1.5 g of fat) increased C max and AUC inf of a single oral 750-mg dose of ceritinib by 45% and 54%, respectively. 11 On the basis of observations from both studies, the improved absorption of ceritinib in the fed state is hypothesized to be due to the enhanced bile salt secretion in the postprandial intestine even with minimal fat intake, which leads to increased micellar solubilization and wetting of the drug, both of which can enhance the dissolution rate. [12] [13] [14] Thus, a low-fat meal with either 1.5 g or 9 g of fat increased the systemic exposure of ceritinib to a similar extent. 11 On the basis of these pharmacokinetics (PK) data, it was determined that avoiding food during dosing of ceritinib at the labeled dose of 750 mg/d is essential, as the intake of food at that dose may increase the occurrence of exposure-dependent toxicities.
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Given the known safety profile of ceritinib, the effect of food on its bioavailability, and the observation that food improved the GI tolerability of other multikinase inhibitors, the ongoing, multicenter, randomized openlabel study ASCEND-8 (NCT02299505) intends to evaluate the systemic exposure and safety profile of 450 mg or 600 mg of ceritinib taken daily with a low-fat meal versus 750 mg daily fasted in patients with ALK-positive NSCLC. Part 1 of the study aimed to determine whether ceritinib with a low-fat meal may enhance GI tolerability in patients with ALK-positive NSCLC while maintaining similar steady-state exposure. Part 2 of the study will evaluate the efficacy and safety of ceritinib, 450 mg or 600 mg, with food versus 750 mg in fasted patients as a starting dose. The results from part 1 are reported in this article.
Patients and Methods

Study Population
Adult patients (age !18 years) were eligible if they had a histologically or cytologically confirmed diagnosis of stage IIIB or IV ALK-positive NSCLC and were treatment naive (except for neoadjuvant/adjuvant systemic therapy, excluding regimens containing an ALK inhibitor [if relapse had occurred >12 months from the end of therapy]) or were previously treated with one prior crizotinib regimen (additionally, !1 systemic anticancer therapy [chemotherapy, biologic therapy, or other investigational agents] was allowed); had a WHO performance score (PS) of 0 to 2; and had asymptomatic or neurologically stable central nervous system metastases. Initially, for all patients, ALK-rearrangement was determined locally by using the U.S. Food and Drug Administration-approved Vysis ALK Break-Apart Fluorescence In Situ Hybridization (FISH) Probe Kit (Abbott Molecular, Des Plaines, IL) and scoring algorithm. After a protocol amendment, treatment-naive patients were required to have their ALK-rearrangement determined by the Ventana Anti-ALK (D5F3) immunohistochemistry (IHC) assay (Ventana Medical Systems, Tucson, AZ) at a Novartis-designated central laboratory. Treatment-naive patients (ALK positive by IHC) needed to have one or more measurable lesions, as defined by Response Evaluation Criteria in Solid Tumors, version 1.1, and confirmed by blinded independent review committee before randomization. The use of acid-reducing agents, including antacids, H 2 antagonists, and proton pump inhibitors (PPIs), was allowed. When the concurrent use of an H 2 antagonist or an antacid with ceritinib was necessary, the H 2 blocker was to be administered 10 hours before or 2 hours after the ceritinib dose and the antacid was to be administered 2 hours before or 2 hours after the ceritinib dose. Patients who received strong inhibitors or strong inducers of cytochrome P-450 3A were excluded. Consumption of grapefruits, pomegranates, star fruits, Seville oranges, or products containing their juice within 3 days before the days of blood sample collection for PK assessment was prohibited. Other key exclusion criteria are available in the Supplementary Appendix.
The study protocol and all amendments were reviewed by the independent ethics committee or institutional review board for each center. This study was conducted according to the ethical principles of the Declaration of Helsinki and the Good Clinical Practice guidelines. Written informed consent was obtained from each patient before randomization.
Study Design
ASCEND-8 is an open-label, randomized, multicenter, parallel design, phase 1 study conducted at 49 centers across 18 countries. Eligible patients were randomized by using interactive response technology in a 1:1:1 ratio to one of three treatment arms: ceritinib, 450 mg with a low-fat meal (fed); ceritinib, 600 mg with a low-fat meal . A low-fat meal (food) defined as approximately 100 to 500 calories and 1.5 to 15 g of fat was used in the ASCEND-8 study given the modest difference in AUC inf between the light snack, low-fat meal, and high-fat meal.
Meal record (for patients in the fed arms) was collected in the clinic on PK sampling days. Compliance with prandial conditions for non-PK sampling days was to be confirmed by the study personnel during study visits (e.g., through patient diaries).
A cycle of treatment was defined as 21 days of oncedaily ceritinib treatment. The study comprised two parts. Part 1 (primary PK analysis) investigated PK exposure to ceritinib, 450 mg fed and 600 mg fed, versus ceritinib, 750 mg fasted, and preliminary safety in previously treated or treatment-naive patients with advanced ALK-positive NSCLC. Part 2 (efficacy analysis) is currently randomly allocating only treatment-naive patients with advanced ALK-positive NSCLC by IHC and will assess efficacy as well as additional safety follow-up.
Treatment with ceritinib continued until the patient experienced unacceptable toxicity, disease progression, or withdrawal of consent and/or at the discretion of the investigator. Patients who had Response Evaluation Criteria in Solid Tumors-defined progressive disease, but who in the opinion of the investigator, would benefit from continued treatment could continue to receive the drug. Patients starting to take the 450-mg or 600-mg fed dose could reduce their daily dose stepwise to a minimum of 150 mg with a low-fat meal. Patients starting to take the 750-mg fasted dose could reduce their dose stepwise to a minimum of 300 mg fasted. All dose reductions were in 150-mg decrements per reduction. Patients were instructed to not make up missed doses or partial doses (defined as a dose that is not taken within 12 hours after the approximate time of the usual daily dosing). That day's dose (or part remaining dose) was omitted and the patient continued treatment with the next scheduled dose on the next day.
Assessments
Blood samples (2 mL each) for a full plasma concentration-time profile of ceritinib were collected over 24 hours on cycle 1 day 1 and on cycle 2 day 1 at the following scheduled time points: before the dose and 1, 2, 4, 6, 8, and 24 hours after the dose. Trough PK samples were collected before the dose on cycle 1 day 8, cycle 1 day 15, and cycle 3 day 1 to cycle 6 day 1. Plasma concentrations of ceritinib were measured by a validated liquid chromatography-tandem mass spectrometry assay. 15 Concentrations below the lower limit of quantification for ceritinib of 1 ng/mL were reported as 0 ng/ mL. The following PK parameters of ceritinib were calculated using the standard noncompartmental method with Phoenix WinNonlin (version 6.2 [Pharsight, Mountain View, CA]): AUC from time zero to 24 hours (AUC 0-24h ), C max , and time at C max (T max ) at cycle 1 day 1 and cycle 2 day 1. Once at least 90 patients (approximately 30 patients in each treatment arm) had been confirmed to be evaluable for PK analysis at steady state (cycle 2 day 1), collection of serial blood samples for full PK profiles on cycle 1 day 1 and cycle 2 day 1 were no longer taken for newly enrolled patients. AEs were coded using the Medical Dictionary for Regulatory Activities, version 19, and graded according to the Common Terminology Criteria for AEs, version 4.03. All patients were followed for AEs and serious AEs (SAEs) for at least 30 days after discontinuation of ceritinib treatment.
Statistical Analysis
The primary PK analysis was based on patients in the PK analysis set (PAS). The PAS included patients with an evaluable full PK profile at steady state (cycle 2 day 1), defined as patients with no vomiting event (within 4 hours after dose administration on the full PK sampling day) and taking the study drug according to the originally assigned dose and prandial condition for at least 5 consecutive days without interruption or dose modification before the PK sampling day (detailed PK evaluability criteria reported in Supplementary Appendix 16 ) . A formal statistical analysis was performed using the PAS for the primary PK parameters at steady state (AUC 0-24h and C max at cycle 2 day 1) to estimate the combined effect of food and ceritinib at a dose of 450 mg and 600 mg on ceritinib PK. AUC 0-24h and C max at cycle 2 day 1 were log-transformed and analyzed with a linear model, with the treatment arm included as a covariate. The between-treatment differences and 90.0% confidence intervals (CIs) were then back-transformed to the original scale to obtain the geometric mean ratios (GMRs) (ceritinib 600 mg fed arm/ceritinib 750 mg fasted arm and ceritinib 450 mg fed arm/ceritinib 750 mg fasted arm) and corresponding 90.0% CIs. For T max , the median and difference in medians between treatment arms were provided.
The safety set included all patients who received at least one dose of ceritinib and was used for all safety analyses. The safety data (including frequency of patients with AEs, SAEs, and GI toxicities of all grades and grade 3 or 4) were summarized by treatment arms. Time to the first grade 1 or higher GI toxicity (nausea, vomiting, and diarrhea) was also summarized by treatment arm.
Results
Patient Disposition
The data cutoff for the primary PK analysis was June 16, 2016. Between April 9, 2015, and June 16, 2016, a total of 137 patients were randomized (1:1:1) to the 450 mg fed arm (n ¼ 44), the 600 mg fed arm (n ¼ 47), and the 750 mg fasted arm (n ¼ 46). Of these 137 patients, all except two (in the 600 mg fed arm) received at least one dose of ceritinib and were included in the safety set. A total of 97 patients (36 in the 450 mg fed arm, 30 in the 600 mg fed arm, and 31 in the 750 mg fasted arm) had evaluable steady-state PK data at cycle 2 day 1 and were included in the PAS (Fig. 1) . The median duration of follow-up (from randomization to data cutoff date) was 4.1 months (range 0.1-13.9). In total, 30 patients (21.9%) discontinued the treatment phase (details are available in Supplementary Table 1 and the Supplementary Appendix).
Patient Demographics and Disease Characteristics
The median age of the patients was 56 years (range 25-86), and most were females (54.7%), were white (67.9%), and had a WHO PS of 0 or 1 (87.6%). Baseline patient demographics and disease characteristics by treatment arm are shown in Table 1 . In general, the demographic characteristics were similar across treatment arms; however, imbalances were noted in sex, WHO PS, and smoking history (details are provided in the Supplementary Appendix).
The disease characteristics of patients in this study were representative of the population of patients with ALK-positive NSCLC. In the 137 randomized patients, the predominant tumor histologic subtype was adenocarcinoma (92.0%). Most of the patients had metastatic (stage IV) NSCLC (97.1%), whereas 2.9% of patients had locally advanced NSCLC (stage IIIb, not suitable for definitive multimodality therapy). The median time from initial diagnosis to randomization was 12.3 months (range 0.7-148.6) (see Table 1 ).
Thirty-nine patients (28.5%) did not receive any prior anticancer regimen (25.0% in the 450 mg fed arm, 31.9% in the 600 mg fed arm, and 28.3% in the 750 mg fasted arm) (see Table 1 ). Twelve (27.3%), 11 (23.4%), 
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The GMRs and corresponding 90% CIs for estimating the effect of food and dose on ceritinib PK are provided in Table 2 , which presents comparisons between the two fed arms (450 mg fed and 600 mg fed) and the 750 mg fasted arm with respect to the primary PK parameters AUC 0-24h and C max at steady state (cycle 2 day 1). Of the 97 patients with evaluable full PK profile at steady state, patients in the 450 mg fed arm demonstrated AUC 0-24h and C max values comparable to those of patients in the 750 mg fasted arm (see Table 2 and Fig. 2 Table 2 and Fig. 2) .
The median T max after multiple dose administration was similar for all three arms (i.e., 6.03 hours, 6 hours, and 5.9 hours for the 450 mg fed, the 600 mg fed, and the 750 mg fasted arms, respectively).
Safety
The median duration of treatment exposure (from first dosing to last dosing date) was 3.6 months for all patients in the safety set (n ¼ 135), and duration was similar for the three treatment arms (median of 3.1 months in the 450 mg fed arm, 3.6 months in the 600 mg fed arm, and 3.7 months in the 750 mg fasted arm) (see Supplementary Table 2 ). The median relative dose intensity was 100% in the 450 mg fed arm, 87.7% in the 600 mg fed arm, and 100% in the 750 mg fasted arm. The number of patients requiring one or more dose reductions was lowest in the 450 mg fed arm (11.4%), followed by in the 750 mg fasted (37.8%) and 600 mg fed arms (52.2%). In the 450 mg fed arm, no dose reductions due to GI toxicities were reported.
An overview of overall safety by treatment arm is shown in Table 3 . Similar proportions of patients in the 450 mg fed arm and the 750 mg fasted arm presented with AEs, AEs suspected to be drug related, SAEs, and AEs associated with study drug discontinuation. All patients reported at least one AE regardless of study drug relationship.
The most frequently reported AEs regardless of study drug relationship were GI toxicities (diarrhea, nausea, and vomiting) ( Table 4 ). The 450 mg fed arm showed the most favorable safety profile for GI toxicities (diarrhea, nausea, and vomiting), presenting a lower proportion of patients with these AEs and no grade 3 or 4 events, study drug discontinuations, or SAEs due to GI toxicities. An overview of GI toxicities (diarrhea, nausea, and vomiting) is shown in Table 5 . Most of the GI toxicities (43.2%) in the 450 mg fed arm were grade 1. Further, no patient required dose adjustment and only one patient required study drug interruption due to GI toxicity (diarrhea) in the 450 mg fed arm (see Table 5 ). The median time to first grade 1 or higher GI toxicity (nausea, diarrhea, or vomiting) was similar among the treatment arms (4.0, 3.0, and 2.5 days in the 450 mg fed arm, 600 mg fed arm, and 750 mg fasted arm, respectively). Other frequently reported AEs were abdominal pain (lower in the 450 mg fed arm [22.7%] than in the 600 mg fed AEs suspected to be related to the study drug were similar across the treatment arms (84.1% in the 450 mg fed arm, 91.3% in the 600 mg fed arm, and 84.4% in the 750 mg fasted arm) (see Table 3 ).
The overall incidence of SAEs was relatively low in the ceritinib 450 mg fed arm (13.6%) and the 750 mg fasted arm (15.6%). The ceritinib 600 mg fed arm had the highest proportion of patients presenting with SAEs (32.6%). There were no SAEs of diarrhea, nausea, or vomiting reported, except for one grade 3 SAE of nausea in the 600 mg fed arm. The number of patients with AEs leading to study drug discontinuation was low (eight patients [5.9%] ) and similar across the treatment arms. Overall, the rate of AEs requiring dose interruption and/ or adjustment was lower in the 450 mg fed arm (31.8%) than in the 600 mg fed arm (65.2%) or the 750 mg fasted arm (48.9%) (see Table 3 ).
No cases of Hy's law, pancreatitis, or Torsade de pointes were reported. One patient (in the 450 mg fed arm) reported interstitial lung disease, which was considered unrelated to the study drug. In total, 12 of 135 patients (8.9%) died during the on-treatment period (first dose date to last dose date plus 30 days). The numbers of on-treatment deaths were similar among the three treatment arms (five patients [11.4%] , four patients [8.7%] , and three patients [6.7%] in the 450 mg fed, 600 mg fed, and 750 mg fasted arms, respectively). Nine patients (6.7%) died of the study indication and the remaining three patients (2.2%) died of AEs (all considered unrelated to ceritinib).
Discussion
Part 1 of ASCEND-8 has demonstrated that ceritinib, 450 mg, taken once daily with food provides systemic exposure similar to that of the currently approved daily dose of 750 mg in a fasted state. In addition, the preliminary safety results demonstrated that a lower dose of ceritinib (450 mg) taken with food reduced the proportion of patients with GI toxicities (diarrhea, nausea, or vomiting) when compared with the 750 mg fasted dose, presenting the most favorable safety profile for GI toxicities when compared with the other treatment arms.
In this study, steady-state PK as assessed by C max and AUC 0-24h was comparable in patients with advanced ALK-positive NSCLC in the 450 mg fed arm and the 750 mg fasted arm but higher in patients in the 600 mg fed arm than in patients in the 750 mg fasted arm (see Table 2 ). The median T max values were similar across all three treatment arms (i.e., w6 h), indicating no detectable effect of food on the time to reach C max . The variability in the ceritinib steady-state PK in all arms was low to moderate, with a coefficient of variation (%) of approximately 40% to 50% for C max and AUC 0-24h . In the 450 mg fed arm, the 90% CIs of the GMRs for both C max and AUC 0-24h were completely contained within the conventional bioequivalence range of 0.8 to 1.25 for the 450 mg fed arm (test) versus the 750 mg fasted arm (reference). This has been observed in spite of the patients taking a daily ceritinib dose along with a meal that allows a wide range of fat (1.5-15 grams of fat) and calorie content (100-500 calories). On the other hand, 600 mg of ceritinib taken with the same type of low-fat meal showed an approximately 25% higher steady-state PK than with 750 mg ceritinib in a fasted state.
Confounding factors such as concomitant medications that may influence the PK interpretation were considered in this study. Acid-reducing agents, including the most potent type (PPIs), were allowed in this study as well as in all other ceritinib patient studies. These agents are not expected to influence the PK results of ceritinib shown in this study, although ceritinib displays pH-dependent solubility in vitro, 17 as it has recently been demonstrated that long-term administration of ceritinib with PPIs does not adversely affect the steady-state PK and efficacy of ceritinib in patients with ALK-positive cancer. 18 Other agents such as cytochrome P-450 3A inhibitors and inducers that may influence ceritinib's PK were excluded from this study.
The 450-mg daily dose of ceritinib taken with food reduced the frequency and severity of the GI toxicities. The GI toxicities diarrhea, nausea, and vomiting in the 450 mg fed arm were mostly grade 1 (43.2%, 29.5%, and 18.2% respectively), with no grade 3 or 4 GI toxicities reported. No patient in 450 mg fed arm had a dose reduction due to GI AEs. In addition, the 450 mg fed arm had the lowest number of patients with AEs requiring dose adjustment or study drug interruption among the three treatment arms and the highest proportion of patients with relative dose intensity of 90% to less than 110%. Compared with the patients in the 750 mg fasted arm, those treated with 600 mg with food showed less GI toxicity. All grades of AEs and AEs leading to study drug discontinuation were observed in similar numbers of patients in both arms, whereas the numbers of SAEs and AEs that required dose adjustments or interruption were higher in the 600 mg fed arm than in the 750 mg fasted arm.
The ceritinib 450 mg fed arm demonstrated improvement in GI tolerability while maintaining steadystate exposure comparable to that of the approved recommended daily dose of ceritinib 750 mg fasted. On the basis of the exposure-safety analysis using data from patients with ALK-positive cancer in ASCEND-1, no apparent trend between systemic exposure and GI toxicities can be identified, 18, 19 suggesting that most GI AEs could be due to the locally high ceritinib concentration in the gut, which leads directly to GI toxicities. Thus, food can improve the GI tolerability of ceritinib by enhancing the absorption of ceritinib in the gut, which leads to less local irritation. 17, 19 The demographics and disease characteristics of patients in this study are consistent with those observed in patients with metastatic ALK-positive NSCLC in other ceritinib studies. This study was conducted with close monitoring of patients and with rigorous study procedures to ensure adherence to the assigned prandial conditions and accurate assessment of PK and safety data. There were well-defined PK evaluability criteria to ensure that only patients who strictly followed the protocol directions with evaluable full PK profile collected at steady state were included in the PK analysis (which included 97 patients of the 137 randomized patients).
Part 1 of this study focused on the PK and preliminary safety data assessed in a heterogeneous patient population that included both previously treated (prior crizotinib and chemotherapy treatment allowed) and treatment-naive patients. A short follow-up was enough to ensure proper steady-state PK assessment. There was no efficacy analysis in part 1 of the study because of the short duration of follow-up and the heterogeneous patient populations with relatively limited sample size. Part 2 of this study is ongoing with the objective of evaluating efficacy among the treatment arms in a homogeneous and larger patient population of treatmentnaive patients with ALK-positive NSCLC, similarly to the recently reported phase 3 study (ASCEND-4), which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy in previously untreated patients with ALK-positive NSCLC. 7 ASCEND-8 results provide insights for management of patients taking ceritinib because it appears that a dose reduction to 450 mg with food for patients with GI toxicities may reduce the frequency and severity of diarrhea, nausea, and vomiting while maintaining the same exposure as the currently approved dose of 750 mg fasted. The study is ongoing, and the three different doses (450 mg fed, 600 mg fed, and 750 mg fasted) will be further evaluated for long-term safety and efficacy.
In conclusion, the steady-state PK and preliminary safety data demonstrated that a once-daily ceritinib dose of 450 mg taken with food presents an exposure similar to that of the currently approved dose of 750 mg fasted. In addition, it may provide a more favorable GI safety profile, with a lower frequency and severity of GI toxicities and fewer dose adjustments and interruptions compared to ceritinib 750-mg fasted dose. Efficacy and long-term safety results will be available once part 2 of the study has been completed.
